RFG - ETF AI Analysis
Top Page
Invesco S&P Midcap 400 Pure Growth ETF (RFG)
Rating:73Outperform
Price Target:―
Positive Factors
Strong Year-To-Date Performance
The ETF has delivered strong gains so far this year, suggesting its growth-focused strategy has been working well in the recent market environment.
Leading Growth Stocks in Top Holdings
Several of the largest positions, such as DigitalOcean, Sterling Infrastructure, and TTM Technologies, have shown strong performance, helping drive the fund’s overall results.
Broad Sector Diversification Within U.S. Midcaps
The fund spreads its investments across many sectors, including industrials, technology, health care, and others, which helps reduce the impact if any single industry struggles.
Negative Factors
Heavy Tilt Toward a Few Key Sectors
Industrials, technology, and health care make up a large share of the portfolio, so weakness in these areas could hurt the ETF more than a more evenly balanced fund.
Short-Term Performance Volatility
The ETF’s recent one-month performance has been weak compared with its stronger longer-term results, showing that returns can be bumpy over shorter periods.
Limited Geographic Diversification
With almost all holdings in U.S. companies, the fund offers little exposure to international markets, which may increase sensitivity to U.S.-specific economic and policy risks.
RFG vs. SPDR S&P 500 ETF (SPY)
AUM351.21M
RegionNorth America
Expense Ratio0.35%
Beta1.05
IssuerInvesco
Inception DateMar 01, 2006
Dividend Yield0.15%
Asset ClassEquity
Index TrackedS&P Mid Cap 400 Pure Growth
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,833
30 Day Avg. Volume6,324
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
73.85Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering101
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RFG Summary
The Invesco S&P Midcap 400 Pure Growth ETF (RFG) tracks the S&P Mid Cap 400 Pure Growth Index, focusing on medium‑sized U.S. companies that are growing quickly. It holds a mix of industrial, technology, and health care businesses such as DigitalOcean Holdings and Arrowhead Pharmaceuticals, giving investors a way to spread their money across many growing firms instead of picking individual stocks. Someone might invest in RFG for long-term growth and diversification within mid-sized companies. A key risk is that growth stocks can be more volatile, so the ETF’s value can rise and fall sharply with the market.
How much will it cost me?The Invesco S&P Midcap 400 Pure Growth ETF (RFG) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This cost is slightly higher than average because the fund is actively managed to focus on mid-cap growth stocks, requiring more research and strategy compared to passively managed ETFs. It’s designed for investors seeking targeted exposure to companies with strong growth potential.
What would affect this ETF?The Invesco S&P Midcap 400 Pure Growth ETF (RFG) could benefit from economic growth and innovation within sectors like Industrials, Health Care, and Technology, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as growth stocks often become less attractive in such environments, or if economic uncertainty impacts mid-cap companies more heavily than larger firms. Regulatory changes or sector-specific disruptions could also influence the performance of its top holdings.
RFG Top 10 Holdings
RFG is leaning hard into U.S. mid-cap growth, with a clear tilt toward industrials and health care. Sterling Infrastructure and MasTec have been more mixed lately, with recent softness that can occasionally act as a speed bump for the fund. On the brighter side, Carpenter Technology and ATI are rising on aerospace and industrial strength, while Arrowhead Pharmaceuticals and Medpace add a punch of biotech momentum, though with some valuation jitters. DigitalOcean brings a tech flair, but its choppy near-term action shows that not every growth story is running smoothly.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 2.52% | $8.66M | $11.92B | 422.38% | 57 Neutral | |
| Sterling Infrastructure | 2.35% | $8.05M | $18.31B | 125.02% | 71 Outperform | |
| Carpenter Technology | 2.32% | $7.97M | $25.82B | 114.81% | 75 Outperform | |
| TechnipFMC | 2.08% | $7.14M | $28.10B | 93.86% | 80 Outperform | |
| Halozyme | 2.05% | $7.05M | $9.79B | 37.14% | 73 Outperform | |
| DigitalOcean Holdings | 2.03% | $6.97M | $13.74B | 370.82% | 73 Outperform | |
| Woodward | 1.83% | $6.28M | $21.30B | 39.90% | 79 Outperform | |
| Medpace Holdings | 1.77% | $6.06M | $16.11B | 32.57% | 79 Outperform | |
| ATI | 1.75% | $6.01M | $25.58B | 155.31% | 78 Outperform | |
| InterDigital | 1.74% | $5.98M | $7.87B | 14.34% | 76 Outperform |
RFG Technical Analysis
Positive
―
Price Trends
62.08
Negative
60.37
Positive
57.27
Positive
Market Momentum
-0.26
Negative
53.06
Neutral
89.03
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RFG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 60.54, equal to the 50-day MA of 62.08, and equal to the 200-day MA of 57.27, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 53.06 is Neutral, neither overbought nor oversold. The STOCH value of 89.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RFG.
RFG Peer Comparison
Comparison Results
Performance Comparison
RFG
Invesco S&P Midcap 400 Pure Growth ETF
61.58
12.05
24.33%
FNY
First Trust Mid Cap Growth AlphaDEX Fund
―
―
―
NUMG
Nuveen ESG Mid-Cap Growth ETF
―
―
―
GLRY
Inspire Faithward Mid Cap Momentum ESG ETF
―
―
―
FRTY
Alger Mid Cap 40 ETF
―
―
―
TMFM
Motley Fool Mid-Cap Growth ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents